Overview

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.
Phase:
N/A
Details
Lead Sponsor:
Corixa Corporation
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Tositumomab I-131